Rapacuronium
Raplon (rapacuronium) is a small molecule pharmaceutical. Rapacuronium was first approved as Raplon on 1999-08-18.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rapacuronium bromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RAPLON | Organon | N-020984 DISCN | 1999-08-18 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
96 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Castration-resistant prostatic neoplasms | D064129 | 9 | 8 | 2 | — | 14 | 29 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 5 | — | — | — | 5 |
| Adenocarcinoma | D000230 | 2 | 3 | — | — | — | 4 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | 2 | 2 | — | — | — | 4 | |
| Neoplasms | D009369 | C80 | 2 | 1 | — | — | 1 | 3 | |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 2 | — | — | 1 | 3 |
| Multiple myeloma | D009101 | C90.0 | 2 | 2 | — | — | — | 2 | |
| Renal cell carcinoma | D002292 | 1 | 1 | — | — | — | 2 | ||
| Triple negative breast neoplasms | D064726 | — | 1 | — | — | — | 1 | ||
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | — | 1 | |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RAPACURONIUM |
| INN | rapacuronium bromide |
| Description | Rapacuronium bromide (brand name Raplon) is a rapidly acting, non-depolarizing aminosteroid neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.
|
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives: neuromuscular blocking agents; quaternary ammonium derivatives: neuromuscular blocking agents |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 156137-99-4 |
| RxCUI | 228530 |
| ChEMBL ID | CHEMBL1201352 |
| ChEBI ID | — |
| PubChem CID | 5311398 |
| DrugBank | DB04834 |
| UNII ID | 65Q4QDG4KC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 81 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,622 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more